News blog

Ones that got away

“This transaction will create a new world-leading specialist dermatology business and re-energise our existing dermatology products.”

Andrew Witty, GSK chief executive, comments on the company’s $3.6bn move for Stiefel Laboratories ().

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE